Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16132
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRivalland, Gareth-
dc.contributor.authorLoveland, Bruce E-
dc.contributor.authorMitchell, Paul L R-
dc.date2015-10-09-
dc.date.accessioned2016-08-16T00:52:37Z-
dc.date.available2016-08-16T00:52:37Z-
dc.date.issued2015-
dc.identifier.citationExpert Opinion on Biological Therapy 2015; 15(12): 1773-1787en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16132-
dc.description.abstractINTRODUCTION: Mucin 1 (MUC1) is particularly well suited as a cancer immunotherapy target due to the elevated protein expression and aberrant forms associated with malignancy. A variety of therapeutic strategies have been explored, including antibodies intended to induce cancer cell destruction, and vaccinations with peptides, tumor extracts, and gene expression systems. AREAS COVERED: MUC1 immunotherapeutic strategies have included vaccination with peptide sequences, glycan molecules, viruses, and dendritic cells, monoclonal antibodies and monoclonal antibody conjugates. Here we review the relevant clinical trials in each field of immunotherapy with particular focus on large and recently published trials. EXPERT OPINION: Long clinical experience in the trial setting has reduced concerns of immunotherapy associated toxicities and inappropriate immune responses, with the main limitation (common to many experimental approaches) being a lack of clinical efficacy. However, there have been sufficient treatment-associated responses to justify continued pursuit of MUC1 targeted immunotherapies. The focus now should be on application to the relevant cancers under appropriate circumstances and combination with the emerging non-specific immunotherapy approaches such as the PD-1 pathway inhibitors.en_US
dc.subjectMucin 1en_US
dc.subjectCancer vaccinesen_US
dc.subjectClinical trialsen_US
dc.subjectDendritic cellsen_US
dc.subjectImmunotherapyen_US
dc.subjectMonoclonal antibodiesen_US
dc.subjectViral vectorsen_US
dc.titleUpdate on Mucin-1 immunotherapy in cancer: a clinical perspectiveen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleExpert Opinion on Biological Therapyen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationBurnet Institute, Centre for Biomedical Research, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/26453294en_US
dc.identifier.doi10.1517/14712598.2015.1088519en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.